Featured Stories
Decision on Pradaxa Bleeding Lawsuit Multidistrict Litigation Expected Soon

Decision on Pradaxa Bleeding Lawsuit Multidistrict Litigation Expected Soon

Victims of alleged Pradaxa injuries are awaiting word on whether their lawsuits will be consolidated in a multidistrict litigation. According to a report from The Madison Record, so far just over two dozen Pradaxa bleeding lawsuits have been filed in federal courts throughout the U.S.

Read More

Medtronic Plans Layoffs, as Infuse Bone Graft Controversy Continues to Weigh on Spinal Business

Medtronic Plans Layoffs, as Infuse Bone Graft Controversy Continues to Weigh on Spinal Business

Medtronic’s spinal division continues to take a huge hit thanks to the controversy surrounding its Infuse Bone Graft product. According to a report from MassDevice.com, the company’s latest earnings report stated that the division saw Infuse sales decline 26% in the first quarter of 2012, and now Medtronic is talking ...

Read More

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

The first test trials in the federal C.R. Bard Avaulta transvaginal mesh litigation will most likely start next year, according to a report from Bloomberg News. About 600 lawsuits involving Bard Avaulta transvaginal mesh products are currently pending in the multidistrict litigation underway Charleston, West Virginia. U.S. District Judge Joseph ...

Read More

Canadian Study Confirms Actos Bladder Cancer Risk

Canadian Study Confirms Actos Bladder Cancer Risk

A new study conducted by Canadian researchers has found that users of the type 2 diabetes drug, Actos (pioglitazone), may face a higher risk of developing bladder cancer than first thought. The study, published in the British Medical Journal, found that taking Actos for two years doubles the likelihood ...

Read More

Canadian Study Finds Actos Raises Bladder Cancer Risk by 22 Percent

Canadian Study Finds Actos Raises Bladder Cancer Risk by 22 Percent

Yet another study is confirming the association between the diabetes drug, Actos, and bladder cancer. This latest research, published today in the Canadian Medical Association Journal, found that taking Actos raised the risk of bladder cancer among diabetics by about one-fifth.

Read More

Actos, Avandia May Up Risk for Diabetic Macular Edema

Actos, Avandia May Up Risk for Diabetic Macular Edema

A newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study, published in the Archives of Internal Medicine, found that type 2 diabetics who use thiazolidinediones, ...

Read More

Pradaxa Associated with more Complications than Warfarin, According to Early Study Findings

Pradaxa Associated with more Complications than Warfarin, According to Early Study Findings

Early results from the largest study to date to compare Pradaxa and warfarin indicate that in a real-world setting, Pradaxa causes more complications than decades-old warfarin. The preliminary study results were announced last week, during the 2012 Thrombosis and Hemostasis Summit of North America.

Read More

Study Finds Plavix May Only Benefit Smokers

Study Finds Plavix May Only Benefit Smokers

An emerging study finds that blood thinner Plavix may only benefit smokers. Plavix (clopidogrel) is prescribed for the prevention of blood clots and heart attacks, and has been linked to serious side effects, including the heart attacks and strokes it is supposed to prevent, gastrointestinal and cerebral bleeding, bleeding ulcers, ...

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

Transvaginal Mesh a Nightmare for Thousands of Women

Transvaginal Mesh a Nightmare for Thousands of Women

Thousands of women who have received transvaginal mesh surgical implants to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP) are now living a nightmare, thanks to debilitating pain, bleeding, infection and other serious complications. According to the Sun-Sentinel, many of the women injured by transvaginal mesh claim ...

Read More

Whistleblower to Receive Record $30 Million Award

A foreign whistleblower will receive an award of over $30 million from the Securities and Exchange Commission (SEC), the agency said on Monday. According to the Wall Street Journal, this is the largest award since the SEC program began in 2011, more than double the highest previous award.

The award comes soon after Attorney General Eric Holder said he wanted to increase whistleblower payouts as an incentive. Continue reading

Posted in Legal News |

Nationwide M&Ms Recall: Allergen Concerns

Last week, Mars Chocolate North America announced a voluntary recall of its M&Ms Brand Theater Box, 3.40 oz, UPC #40000294764 because the box may contain peanut butter M&Ms, though peanut butter– an allergen – is not listed on the outside of the box.

The inside package is correctly labeled with ingredients and allergy information, according to the recall notice on the Food and Drug Administration (FDA) web site. People with peanut allergies run the risk of a serious or life-threatening reaction if their theater box contains an M&Ms Brand Peanut Butter bag and they consume the product. No adverse reactions have been reported to date. Continue reading

Posted in Food Products, Health Concerns |

Medtronic Makes Final Payment to Settle Kickbacks Lawsuit over CRM products

Medtronic has made the final payment in an $11.1 million settlement over allegations that it used kickbacks to promote the use of its cardiac rhythm products. According to a press release issued by the office of Eric Schneiderman, the U.S. Attorney General for New York, the company’s final payment of $362,362 will be split among the Medicaid programs in 46 states and the District of Columbia. Continue reading

Posted in Legal News |

Bipartisan Congressional Group Seeks Reauthorization of Zadroga 9/11 Act

A bipartisan group of U.S. senators and representatives has introduced legislation to reauthorize the James Zadroga 9/11 Health and Compensation Act, to continue programs providing medical treatment and compensation to 9/11 responders for another 25 years.

Senators Kirsten Gillibrand and Chuck Schumer and seven other senators introduced the legislation in the Senate. The House bill was introduced by Representatives Carolyn Maloney, Jerrold Nadler, Peter King, and 37 others. New York City’s mayor, Bill de Blasio, along with 9/11 first responders, community survivors, and union leaders joined the effort to reauthorize the programs, 9/11 Health Watch reports. Continue reading

Posted in Health Concerns, Toxic Substances, Zadroga Act Claims |

Study: Artificial Sweeteners May Raise Blood Sugar, Promote Obesity

Artificial-Sweeteners-May-Raise-Your-Blood-SugarA new study involving artificial sweeteners has found that the additives may be making Americans fatter.

The study revealed that artificial sweeteners may trigger “dramatic” blood sugar disturbances in people and mice. This appears to happen because of the way in which the sweetening additives alter the gut’s bacterial populations, or microbiota, according to the National Post. The microbiota are an intricate ecosystem of bacteria and microorganisms that live in the gut.

The study, conducted by scientists in Israel, was released Wednesday by the journal, Nature. The research calls for a reassessment of the use of artificial sweeteners, which are one of the most widely used food additives globally, wrote the National Post. Continue reading

Posted in Defective Products, Food Products |

Study Finds No Evidence of Effectiveness and Safety of Newer Joint Replacement Devices

Joint-Replacement-DevicesIn light of the failure of articular surface replacement and large head size metal-on-metal joint replacement devices, scientists, doctors, and health policy professionals have highlighted the need for a more thorough and evidence-based introduction of joint replacement devices and for the development of an infrastructure for timely evaluation of these devices.

In a recently published study in the BMJ, a group of researchers, led by Dr. Marc J. Nieuwenhuijse, systematically evaluated the evidence concerning the introduction of five innovative, relatively recent, and already widely implemented devices used in total joint replacement. The research team evaluated comparative data from clinical trials, observational studies, and large national arthroplasty registries to study effectiveness and safety of the new devices versus existing, well proven, comparable devices. The five technologies reviewed are ceramic-on-ceramic bearings, modular femoral necks, and uncemented monoblock (not metal-on-metal) acetabular cups in total hip replacement, and high flexion implants and gender-specific implants in total knee replacement. Continue reading

Posted in Defective Medical Devices, Metal Hip Implants |

Expert Witness in Chantix Case Seeks Pfizer Documents

Chantix-CaseAn expert witness in the multidistrict litigation over Chantix (varenicline), a smoking cessation drug, has moved to unseal court records in advance of a Food and Drug Administration (FDA) meeting to consider whether the drug should carry a warning about suicide risk.

Dr. Joseph Glenmullen, an expert causation witness for the plaintiffs, and Thomas Moore, a drug-safety researcher, called for the unsealing of thousands of Pfizer Inc. internal documents, National Law Journal reports. Both wrote about how smoking cessation treatments like Chantix are associated with a higher incidence of depression, suicide and violence toward other people. The two experts “want to ensure the public debate about the psychiatric side effects of Chantix includes a balanced scientific record, which was examined in depth in the Chantix litigation,” according to court documents.  The FDA meeting is scheduled for Oct. 16. Continue reading

Posted in Chantix, Pharmaceuticals |

Exxon’s Attempt to De-Certify Class Action Lawsuit is Countered

Exxons-Attempt-to-De-Certify-Class-Action-LawsuitExxon Mobil’s attempt to de-certify the class action status of a couple’s lawsuit should be denied, the couple’s attorney argued. According to Arkansas Democrat Gazette, a federal judge granted class action status to the lawsuit, which was filed over an oil spill in Mayflower. Exxon Mobil has petitioned to appeal this decision. Continue reading

Posted in Legal News |

FDA Continues to Express Concern Regarding e-Cigarettes

electronic-cigaretteThe U.S. Food and Drug Administration (FDA) has stated that the exact health effects of e-cigarettes remain unknown. E-cigarettes provide a different nicotine delivery system that, instead of providing smoke, provides vapor.

Not unexpectedly, the makers of e-cigarettes argue that their products are safer than traditional cigarettes; however, the FDA has questions concerning the fairly new nicotine products, according to Daily News Journal. “While e-cigarette aerosol may contain fewer toxicants than cigarette smoke, studies evaluating whether e-cigarettes are less harmful than cigarettes are inconclusive,” the FDA indicated in a recent report. The agency also questioned claims that e-cigarettes may be of help in smoking cessation, indicating in the report that, “No e-cigarette has been approved by FDA as a cessation aid.” Continue reading

Posted in Defective Products, Health Concerns |

Portico TAVR Heart Device Implants Halted Over Safety Concerns

Portico-TAVR-Heart-Device-Implants-HaltedDevice maker St. Jude Medical has halted implantation of the Portico transcatheter aortic valve replacement (TAVR) over safety concerns that surfaced in U.S. clinical trials.

The Portico TAVR device is intended for patients with severe aortic stenosis (narrowing) who are at high risk for open-heart valve replacement surgery or who cannot have surgery. In an email to Medscape, the company confirmed that it had halted implantation worldwide while evaluating “recent cases of reduced valve leaflet mobility that were reported from a small number of CT scans performed approximately 30 days after implant in the U.S. IDE [investigational device exemption] study.” Continue reading

Posted in Defective Medical Devices |

© 2005-2014 Parker Waichman LLP ®. All Rights Reserved.